Skip to main content
. 2023 Jun 1;13(2):1–13. doi: 10.37796/2211-8039.1403

Fig. 6.

Fig. 6

Mechanistic pathways for drugs and their targets under trial. PD-L1: Programmed cell death –ligand 1. EGFR: Epidermal growth factor receptor. VEGFR: Vascular endothelial growth factor receptor. IDH1 & IDH2: Isocitrate Dehydrogenase 1&2. TK: Tyrosine kinase. CTLA-4: Cytotoxic T Lymphocyte-associated antigen. CTL: Cytotoxic T Lymphocytes.